Compare ACR & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACR | ARCT |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.2M | 194.1M |
| IPO Year | N/A | N/A |
| Metric | ACR | ARCT |
|---|---|---|
| Price | $20.01 | $6.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $24.50 | ★ $38.44 |
| AVG Volume (30 Days) | 43.9K | ★ 627.7K |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.65 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | $88,952,000.00 | ★ $97,601,000.00 |
| Revenue This Year | $4.05 | N/A |
| Revenue Next Year | $0.38 | N/A |
| P/E Ratio | $21.10 | ★ N/A |
| Revenue Growth | ★ 14.87 | N/A |
| 52 Week Low | $15.64 | $5.85 |
| 52 Week High | $24.61 | $24.17 |
| Indicator | ACR | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 28.77 | 47.68 |
| Support Level | $23.48 | $6.02 |
| Resistance Level | $21.89 | $6.75 |
| Average True Range (ATR) | 0.74 | 0.30 |
| MACD | -0.39 | 0.16 |
| Stochastic Oscillator | 3.62 | 69.87 |
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.